It is important to examine the cytochrome P450 2C19 (CYP2C19) genetic contribution to
drug disposition and responses of CYP2C19 substrates during drug development. Design of …

The creation of virtual populations allows the estimation of pharmacokinetic parameters,
such as metabolic clearance in extreme individuals rather than the 'average human' …

Significant inter-individual variability of exposure for CYP2C19 substrates may be only partly
due to genetic polymorphism. Therefore, the in vivo inter-individual variability in hepatic …

Aims Previous studies demonstrated direct correlation between CYP2C19 genotype and
BMS‐823778 clearance in healthy volunteers. The objective of the present study was to …

Minimizing interindividual variability in drug exposure is an important goal for drug
discovery. The reliability of the selective CYP2D6 inhibitor quinidine was evaluated in a …

We present a unified quantitative approach to predict the in vivo alteration in drug exposure
caused by either cytochrome P450 (CYP) gene polymorphisms or CYP-mediated drug–drug …

Polymorphisms in cytochrome P450 enzymes can significantly alter the rate of drug
metabolism, as well as the extent of drug-drug interactions. Individuals who homozygotically …

Physiologically based pharmacokinetic (PBPK) modeling has a number of applications,
including assessing drug–drug interactions (DDIs) in polymorphic populations, and should …

Abstract Background and Objective Cytochrome P450 (CYP) 2C9 is the most common
CYP2C enzyme and makes up approximately onethird of total CYP protein content in the …

Understanding the influence of ethnicity on drug exposure is key to patient safety and could
minimize repetitive clinical studies. This analysis aimed to evaluate the ability of …